Page 2 - Interpace Diagnostics News Today

PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling...

AWH earnings call for the period ending March 31, 2021.

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Interpace Biosciences Announces First Quarter 2021 Financial and Business Results Interpace Biosciences, Inc.May 11, 2021 GMT   ● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business       ADVERTISEMENT PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today...

Dear Shareholders, As the newly appointed President and CEO of Interpace I want to take a moment to formally introduce myself and share the new vision and mission for this Company as it relates to our core capabilities, growth prospects and directional outlook for this year and beyond. I joined Interpace with significant leadership experience, including with several specialty clinical laboratories. This includes serving as President & CEO of Boston Heart Diagnostics, Viracor-IBT Laboratories ...

Interpace Biosciences Announces CFO Leadership Transition February 04, 2021 16:42 ET | Source: Interpace Biosciences, Inc. Interpace Biosciences, Inc. UNITED STATES PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace’s Chief Financial ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and ... Interpace Biosciences, Inc.January 20, 2021 GMT Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior Year Estimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 million Realized Reimbursement on Higher ThyGeNEXT Pricing ...